Immune checkpoint inhibitors in EGFR-mutant non-small cell lung cancer: A systematic review
- 19 July 2023
- journal article
- review article
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 119, 102602
Abstract
No abstract availableKeywords
Funding Information
- Ministero dell'istruzione dell'università e della ricerca
- Ministero della Salute
This publication has 81 references indexed in Scilit:
- Checkpoint Inhibitors in Metastatic EGFR- Mutated Non–Small Cell Lung Cancer—A Meta-AnalysisJournal of Thoracic Oncology, 2017
- Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort studyThe Lancet Oncology, 2017
- Immune-modulating effects of bevacizumab in metastatic non-small-cell lung cancer patientsCell Death Discovery, 2016
- Nivolumab Monotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2016
- Nivolumab in Combination With Platinum‐Based Doublet Chemotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2016
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung CancerNew England Journal of Medicine, 2015
- Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancerScience, 2015
- Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigensNature, 2014
- Incidence of EGFR Exon 19 Deletions and L858R in Tumor Specimens From Men and Cigarette Smokers With Lung AdenocarcinomasJournal of Clinical Oncology, 2011
- The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patientsCancer Immunology, Immunotherapy, 2008